Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Breast Cancer

NCT00669591 is registered in ClinicalTrials.gov with Peregrine Pharmaceuticals as lead sponsor.

NCT NCT00669591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00669591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Peregrine Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
August 31, 2010
Enrollment
46 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer